Inhalation Sciences receives new order worth 360,000 SEK from long-term global pharma client
(Stockholm, 5 September 2022) Inhalation Sciences AB (ISAB) has received a purchase order worth 360,000 SEK for development and required software update work from a long-term client, a leading global pharmaceutical company.The client has an extensive generics pipeline and robust R&D organisation. It has ISAB’s high-precision aerosol generation system PreciseInhale® installed in-house, as well as its in vitro lung simulation module DissolvIt®. Prior to purchase and installation, the client carried out a series of successful clinical research projects with Inhalation Research Services - ISAB’